RECRUITING

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

Official Title

Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy

Quick Facts

Study Start:2024-10-15
Study Completion:2026-10-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06554288

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:5 Years to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Ages 5-17 years of age
  2. * Diagnosis of cerebral palsy and dystonia causing interference
  3. * Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
  4. * Parent/legal guardian is willing and able to provide informed permission/assent for the study
  1. * Previously or currently taking trihexyphenidyl
  2. * Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
  3. * A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements

Contacts and Locations

Study Contact

Rose Gelineau-Morel, MD
CONTACT
816-302-3331
rngelineaumorel@cmh.edu
Rachel Nass
CONTACT
8166011354
rnass@cmh.edu

Principal Investigator

Rose Gelineau-Morel, MD
PRINCIPAL_INVESTIGATOR
Children's Mercy Kansas City

Study Locations (Sites)

Children's Mercy Hospital Kansas City
Kansas City, Missouri, 64108
United States

Collaborators and Investigators

Sponsor: Children's Mercy Hospital Kansas City

  • Rose Gelineau-Morel, MD, PRINCIPAL_INVESTIGATOR, Children's Mercy Kansas City

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-15
Study Completion Date2026-10-31

Study Record Updates

Study Start Date2024-10-15
Study Completion Date2026-10-31

Terms related to this study

Keywords Provided by Researchers

  • Pediatric
  • Cerebral Palsy
  • Dystonia
  • Pharmacogenomics
  • Trihexyphenidyl

Additional Relevant MeSH Terms

  • Pediatric Disorder
  • Genetic Predisposition
  • Dystonia, Secondary
  • Dystonia
  • Cerebral Palsy, Dystonic-Rigid
  • Cerebral Palsy, Dyskinetic
  • Trihexyphenidyl Adverse Reaction
  • Pharmacogenomic Drug Interaction